Three Hoosier Cancer Research Network genitourinary studies were featured during the American Society of Clinical Oncology Genitourinary (GU) Cancers Symposium in San Francisco, CA on February 16-18, 2023.

Investigators were invited to attend the HCRN GU clinical trial working group in-person meeting in San Francisco on February 17^th at 6 AM PT / 8 AM CT / 9 AM ET. Investigators interested in joining the clincial trial working group can find more information here.

HCRN GU16-260

Abstract #698 | Poster #J11

David A. Braun, MD, PhD will present abstract titled “Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy” during Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers within the translational research, tumor biology, biomarkers and pathology sub track on February 18at 8 AM PT.

Authors include David A. Braun, Kelly Street, Opeyemi Jegede, Neil Ruthen, Miya Hugaboom, Nicholas R Schindler, David F. McDermott, Elizabeth R. Plimack, Jeffrey A. Sosman, Naomi B. Haas, Michael E. Hurwitz, Hans J. Hammers, Sabina Signoretti, Michael Atkins, Catherine J. Wu

Participating institutions include Yale University School of Medicine, Keck School of Medicine of USC, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Fox Chase Cancer Center, Northwestern University, University of Pennsylvania-Abramson Cancer Center, UT Southwestern Medical Center, Brigham and Women’s Hospital.

HCRN GU17-326

Abstract #668 | Poster #G19

Roberto Pili, MD of University at Buffalo will present the abstract titled “A phase II study to evaluate the safety, pharmacodynamics and efficacy of entinostat in combination with nivolumab plus ipilimumab in patients with renal cell carcinoma previously treated with nivolumab plus ipilimumab or nivolumab alone” during Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers within the therapeutics sub track on February 18 at 8 AM PT.

Authors include Roberto Pili, Nabil Adra, Theodore F. Logan, Heather Burney, Michael B. Atkins

HCRN GU16-257

Abstract #447 | Poster #C3

Matt Galskey, MD of Mount Sinai presented the abstract titled “Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC)” during Poster Session B: Prostate Cancer and Urothelial Carcinoma.

Authors include Matt D. Galsky, Siamak Daneshmand, Sara C Lewis, Kevin G. Chan, Tanya B. Dorff, Jeremy Paul Cetnar, Ronac Mamtani, Christos Kyriakopoulos, Mahalya Gogerly-Moragoda, Sudeh Izadmehr, Menggang Yu, Qianqian Zhao, Tomi Jun, Reza Mehrazin, John P. Sfakianos, Sumanta Monty Pal

About Hoosier Cancer Research Network:

Hoosier Cancer Research Network conducts innovative cancer research in collaboration with academic and community physicians and scientists across the United States. The organization provides comprehensive clinical trial management and support, from conception through publication. Created in 1984 as a program of the Walther Cancer Institute, Hoosier Cancer Research Network became an independent nonprofit clinical research organization in 2007. Since its founding, Hoosier Cancer Research Network has conducted more than 230 trials in a variety of cancer types and supportive care, resulting in more than 350 publications. More than 9,000 subjects have participated in Hoosier Cancer Research Network clinical trials.